VanEck Biotech ETF
BBH
115 hedge funds and large institutions have $147M invested in VanEck Biotech ETF in 2022 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 23 increasing their positions, 35 reducing their positions, and 21 closing their positions.
321% more call options, than puts
Call options by funds: $1.02M | Put options by funds: $243K
0.2% more ownership
Funds ownership: 30.44% → 30.64% (+0.2%)
9% less funds holding
Funds holding: 126 → 115 (-11)
14% less capital invested
Capital invested by funds: $171M → $147M (-$23.5M)
34% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 35
38% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 21
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TIA
Traphagen Investment Advisors
Oradell,
New Jersey
|
+$8.97M |
| 2 |
CIG
Consolidated Investment Group
Englewood,
Colorado
|
+$2.92M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$2.47M |
| 4 |
CCA
Conservest Capital Advisors
Wynnewood,
Pennsylvania
|
+$1.85M |
| 5 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
+$1.69M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$9.88M |
| 2 |
Morgan Stanley
New York
|
-$2.7M |
| 3 |
Chevy Chase Trust
Bethesda,
Maryland
|
-$2.61M |
| 4 |
FFN
Focus Financial Network
Minneapolis,
Minnesota
|
-$2.15M |
| 5 |
CIBC Private Wealth Group
Atlanta,
Georgia
|
-$1.23M |
BBH Hedge Fund Activity: Q1 2022 in Review
115 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in VanEck Biotech ETF (BBH) for Q1 2022, worth a combined $147M — down 14% from $171M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of BBH and 13 opened new positions — a net loss of 8 holders — while 35 trimmed existing stakes and 23 added.
The largest buyer was Traphagen Investment Advisors, adding an estimated $8.97M. The largest seller was Bank of America, cutting an estimated $9.88M.
- 115 institutional investors held VanEck Biotech ETF (BBH) as of Q1 2022, down from 126 in Q4 2021.
- Funds reported $147M of VanEck Biotech ETF stock for Q1 2022, down 14% quarter-over-quarter.
- 13 funds opened new VanEck Biotech ETF positions in Q1 2022 and 21 closed out, a net change of -8 holders.
- The largest VanEck Biotech ETF buyer in Q1 2022 was Traphagen Investment Advisors, an estimated $8.97M added.
- The largest VanEck Biotech ETF seller in Q1 2022 was Bank of America, an estimated $9.88M sold.
Based on aggregated 13F filings for Q1 2022.